Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
PURPOSE: This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND ME...
Main Authors: | Ramalingam, S, Blackhall, F, Krzakowski, M, Barrios, C, Park, K, Bover, I, Seog Heo, D, Rosell, R, Talbot, D, Frank, R, Letrent, S, Ruiz-Garcia, A, Taylor, I, Liang, J, Campbell, A, O'Connell, J, Boyer, M |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
2012
|
פריטים דומים
-
ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING
מאת: Blackhall, F, et al.
יצא לאור: (2012) -
Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
מאת: Justin P Williams, et al.
יצא לאור: (2014-01-01) -
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
מאת: Ferdows Ather, et al.
יצא לאור: (2013-01-01) -
Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib
מאת: Jian Liu, et al.
יצא לאור: (2024-01-01) -
Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation
מאת: Yujing Wang, et al.
יצא לאור: (2024-12-01)